Finally, the CAV1 deletion being present in up to 45% of all SMZL cases suggests that generating a MYC-Tg-Cav1−/− mouse could serve as a more representative clinical mimic of SMZL. The gene discussed is CAV1; the disease is splenic marginal zone lymphoma.